Baseline and early changes in eosinophil count and neutrophil-to-eosinophil ratio predict outcomes in metastatic renal cell carcinoma treated with nivolumab

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F25%3A10001431" target="_blank" >RIV/00064190:_____/25:10001431 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/25:00143792

Výsledek na webu

<a href="https://doi.org/10.1038/s41598-025-32593-8" target="_blank" >https://doi.org/10.1038/s41598-025-32593-8</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41598-025-32593-8" target="_blank" >10.1038/s41598-025-32593-8</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Baseline and early changes in eosinophil count and neutrophil-to-eosinophil ratio predict outcomes in metastatic renal cell carcinoma treated with nivolumab

Popis výsledku v původním jazyce

The role of eosinophils in patients with cancer receiving systemic therapy based on immune checkpoint inhibitors (ICIs) has become a subject of increasing interest. The aim of the present study was to assess the prognostic role of absolute eosinophil count (AEC) and neutrophil-to-eosinophil ratio (NER) in patients with metastatic renal cell carcinoma (mRCC) receiving nivolumab. The associations of AEC and NER at baseline and their relative changes (Delta) after one month of nivolumab therapy with progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analyzed. In total, 458 patients were included. Baseline AEC &gt;= 70 cells/mu L (PFS: HR: 0.663, p = 0.009; OS: HR: 0.583, p = 0.002), AEC one month after nivolumab initiation &gt;= 70 cells/mu L (PFS: HR: 0.544, p = 0.001; OS: HR: 0.331, p &lt; 0.001) and NER &lt; 65 one month after nivolumab initiation (PFS: HR: 0.552, p &lt; 0.001; OS: HR: 0.326, p &lt; 0.001) was associated with superior PFS and OS, and baseline NER &lt; 65 was associated with superior OS (HR: 0.664, p = 0.014). Regarding early dynamics, Delta NER &gt;= 125% was associated with inferior PFS (HR: 1.950, p = 0.001) and OS (HR: 2.680, p &lt; 0.001), and Delta AEC &lt;-30% was associated with inferior OS (HR: 2.132, p &lt; 0.001). Higher ORR was associated with baseline AEC &gt;= 70 cells/mu L (p = 0.048), baseline NER &lt; 65 (p = 0.010); and NER one month after nivolumab initiation &lt; 65 (p = 0.025). The results of the present study suggest that eosinophil-based blood parameters including AEC and NER and their early dynamics during the course of treatment with nivolumab are promising and readily available prognostic biomarkers in patients with mRCC.

Název v anglickém jazyce

Baseline and early changes in eosinophil count and neutrophil-to-eosinophil ratio predict outcomes in metastatic renal cell carcinoma treated with nivolumab

Popis výsledku anglicky

The role of eosinophils in patients with cancer receiving systemic therapy based on immune checkpoint inhibitors (ICIs) has become a subject of increasing interest. The aim of the present study was to assess the prognostic role of absolute eosinophil count (AEC) and neutrophil-to-eosinophil ratio (NER) in patients with metastatic renal cell carcinoma (mRCC) receiving nivolumab. The associations of AEC and NER at baseline and their relative changes (Delta) after one month of nivolumab therapy with progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analyzed. In total, 458 patients were included. Baseline AEC &gt;= 70 cells/mu L (PFS: HR: 0.663, p = 0.009; OS: HR: 0.583, p = 0.002), AEC one month after nivolumab initiation &gt;= 70 cells/mu L (PFS: HR: 0.544, p = 0.001; OS: HR: 0.331, p &lt; 0.001) and NER &lt; 65 one month after nivolumab initiation (PFS: HR: 0.552, p &lt; 0.001; OS: HR: 0.326, p &lt; 0.001) was associated with superior PFS and OS, and baseline NER &lt; 65 was associated with superior OS (HR: 0.664, p = 0.014). Regarding early dynamics, Delta NER &gt;= 125% was associated with inferior PFS (HR: 1.950, p = 0.001) and OS (HR: 2.680, p &lt; 0.001), and Delta AEC &lt;-30% was associated with inferior OS (HR: 2.132, p &lt; 0.001). Higher ORR was associated with baseline AEC &gt;= 70 cells/mu L (p = 0.048), baseline NER &lt; 65 (p = 0.010); and NER one month after nivolumab initiation &lt; 65 (p = 0.025). The results of the present study suggest that eosinophil-based blood parameters including AEC and NER and their early dynamics during the course of treatment with nivolumab are promising and readily available prognostic biomarkers in patients with mRCC.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10700 - Other natural sciences

Projekt

<a href="/cs/project/LX22NPO5102" target="_blank" >LX22NPO5102: Národní ústav pro výzkum rakoviny</a><br>

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

SCIENTIFIC REPORTS

ISSN

2045-2322

e-ISSN

—

Svazek periodika

16

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

12

Strana od-do

nestránkováno

Kód UT WoS článku

001667610600001

EID výsledku v databázi Scopus

2-s2.0-105028305510